Current PBS spend will not be enough to deliver access

July 26, 2019 Latest News News of the Day

This is a preview of subscriber content

Subscribe now to continue reading.

Medicines Australia says Australia cannot deliver patient access to new medicines and biotherapeutics under the existing proportion of PBS spending invested directly on medicines. …

Subscribe now to continue reading.

Latest Video

AstraZeneca confirms pricing the issue, and acts to create a patient access program
June 16, 2026 - Latest News
When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution
June 16, 2026 - Latest News
High Court to decide on patent‑term extensions for formulations as GBMA intervenes
June 15, 2026 - Latest News
Approach policy and pricing negotiations like planning for a product launch
June 15, 2026 - Latest News
Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment
June 15, 2026 - Australian Biotech

Current PBS spend will not be enough to deliver access

This is a preview of subscriber content

Latest Video

Most Read

AstraZeneca confirms pricing the issue, and acts to create a patient access program

When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution

High Court to decide on patent‑term extensions for formulations as GBMA intervenes

Approach policy and pricing negotiations like planning for a product launch

Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment

New Stories

Australian company partners to take innovative therapy to Asia

Novartis names interim leader for Australia and NZ after Country President departs

These outcomes are mostly about the choices Australia is making

AstraZeneca confirms pricing the issue, and acts to create a patient access program

When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution

Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder

Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment

Sign In

Current PBS spend will not be enough to deliver access

This is a preview of subscriber content

Latest Video

Most Read

AstraZeneca confirms pricing the issue, and acts to create a patient access program

When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution

High Court to decide on patent‑term extensions for formulations as GBMA intervenes

Approach policy and pricing negotiations like planning for a product launch

Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment

Follow Us

New Stories

Australian company partners to take innovative therapy to Asia

Novartis names interim leader for Australia and NZ after Country President departs

These outcomes are mostly about the choices Australia is making

AstraZeneca confirms pricing the issue, and acts to create a patient access program

When good policy becomes self defeating, Australia must at least have a discussion about the obvious solution

Entropy Neurodynamics clears safety hurdle for IV psilocin trial in binge eating disorder

Paradigm reaches global milestone as Phase 3 osteoarthritis trial completes enrolment